Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVC 203

Next Previous
Drug Profile

AVC 203

Alternative Names: AVC-203

Latest Information Update: 04 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AvenCell Europe
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Diffuse large B cell lymphoma

Most Recent Events

  • 29 Jul 2025 AvenCell plans a phase I trial for B cell lymphoma (Second-line therapy or greater) (Parenteral), in second half of 2025
  • 09 Dec 2023 Pharmacodynamics data from a preclinical studies in Diffuse large B cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
  • 05 Apr 2023 AVC 203 is available for licensing as of 05 Apr 2023. https://avencell.com/about/ (AvenCell Europe pipeline, April 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top